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Abstract 
Dalton Michael Sheffield: Assessing the Effects of Antioxidants on Oxidative Stress in 
Triple-Negative Breast Cancer Cells via Protein Carbonylation 
Breast cancer is a highly complex, heterogeneous disease, and potential effective 
treatment options are being continuously researched in order to provide a method of 
halting cancer growth and metastasis. One area in particular involves alleviating 
oxidative stress within cancer cells. Oxidative stress is generally defined as an imbalance 
between oxidant and antioxidant species in favor of the oxidants. Cancer cells use this 
oxidative stress to initiate carcinogenesis in cells through different mechanisms, and 
protein carbonylation is a primary biomarker used to quantify oxidative stress levels. 
Antioxidant compounds are those used to alleviate oxidative stress within cells. Here 
breast cancer cells with compounds of varying antioxidant capacity in order to assess 
their effectiveness in combating oxidative stress. After the cells were treated, their 
proteins were extracted, and an oxyblot protocol was then performed to determine the 
degree of protein carbonylation present in each sample. In the experiments, it was 
observed that cells treated with vitamin E exhibited significant levels of oxidative stress, 
and cells treated with CoQ10 and lovastatin exhibited little to no change in levels of 
oxidative stress. The findings on vitamin E were of more interest because vitamin E has 
been used as an antioxidant in the past, but the findings in this paper show it actually 
enhanced protein carbonylation within cells. 
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Chapter 1: Overview of Breast Cancer, Lipid Metabolism, and Oxidative Stress 
1.) The Etiology and Treatment of Breast Cancer 
A.)	Etiology	
Cancer is a major public health problem worldwide and the second leading cause 
of death in the United States. For 2019, 1,762,450 new cancer cases and 606,880 cancer 
deaths are projected to occur in the United States (Siegel 2019), approximately 4,800 new 
cases and 1,700 deaths a day. Furthermore, breast cancer is the most frequently occurring 
cancer among women. In 2015, there were an estimated 1,384,558 new breast cancer 
diagnoses worldwide and nearly 459,000 breast cancer-related deaths (Tao 2015). 
According to the American Cancer Society, approximately one in eight women will 
develop breast cancer over the course of their life. Breast cancer is an extremely complex 
and heterogeneous disease that is still not fully understood, even after years of research. 
A meta-analysis of nine studies showed that hyper-methylation of BRCA1 gene is a high 
risk factor for developing breast cancer (Tao 2015), which helps establish the foundations 
of its notoriety as a genetic disease. However, while breast cancer is a genetic disease, its 
inherited, genetic underpinnings are not the sole determinants of its pathology. Several 
GWAS studies have shown that susceptibility genes and genomic sequences account for 
less than one-third of all inherited breast cancers, with BRCA1 and BRCA2 accounting for 
85% of all hereditary breast cancers (Althuis 2004). Although there are some genetic 
elements of breast cancer that are well-defined in their impact, such as BRCA1 and 
BRCA2, most of the women who develop breast cancer do not present a clear, concise
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risk profile, with only 5–10% of all breast cancers considered due to mutations in 
inherited high penetrance (Althuis 2004). Instead, breast cancer is heavily influenced by a 
combination of age, personal or family history, reproductive and hormonal factors, post-
menopausal obesity, parity, and exogenous hormone use alongside genetic 
predispositions. These factors will be discussed later in this chapter. 
As previously stated, breast cancer is a heterogeneous disease that is affected by 
non-genetic factors as much as genetic ones, so breast cancer’s genetic component is still 
vital in understanding this complex disease. The most inherited breast cancer genes are 
BRCA1 and 2. These genes facilitate the repair of DNA strand breaks and certain founder 
mutations occur in the specific ethnic populations. BRCA2 associated tumors are of a 
higher grade, ER-positive, and they are unlikely to express HER2 receptor as opposed to 
BRCA1 which are mainly triple negative (Libson 2014). Genetic mutations also play a 
role in both inherited and sporadic breast cancer. P53 mutations are present in nearly 40% 
of human breast cancer acquired as a defect, with high penetrance genes being 
responsible for 5%–10% of all breast cancers (Libson 2014). Overall, the etiology of 
breast cancer cannot be concisely defined due to the heterogeneity of the disease process, 
and dominant gene mutations appear to be present in only small numbers of breast 
cancers, with the most common being BRCA1 and BRCA2. Instead, it is suggested that 
gene variations due to single nucleotide polymorphisms, or SNPs, likely explain the 
heterogeneous nature of breast cancer and the differences among individuals with regard 
to tumor behavior (Tao 2015).  
Several examples of non-genetic factors that significantly impact the likelihood of 
developing this disease range from the age at which women conceive their first child to 
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the use of exogenous hormones over the course of one’s life. Interestingly, the age at 
which women conceive their first child also plays a substantial enough role in influencing 
one’s risk of developing breast cancer. Delayed childbearing was more consistently 
associated with an increased risk of developing ER-positive than ER-negative breast 
cancers. The highest risks were observed among women conceiving their first child at a 
later age, with risk estimates ranging from 1.4–2.6. In addition, three of the six studies 
assessing joint PR/ER expression found very modest elevation in hormone receptor-
positive, but not hormone receptor-negative tumors (Althuis 2004).  
The age at which women experience menarche, the first occurrence of 
menstruation, is also believed to affect one’s risk of developing breast cancer. 
Epidemiological investigations suggested that breast cancer risk associated with a young 
age at menarche was more pronounced among premenopausal women, and women who 
did experience menarche at a young age were more likely to develop ER/PR positive 
tumors than ER/PR negative ones. While older age at menarche was not differentially 
associated with increased breast cancer risk when defined by ER or PR status, later 
menarche was not associated with reduced risk of developing ER-negative/ER tumors in 
five of the studies examined (Althuis et al. 2004). The associated risk for later menarche 
was similar for ER-positive/PR-positive and ER-negative/PR-negative tumors as well. In 
addition to age at menarche, women who experienced post-menopausal obesity were at 
an increased risk to develop breast cancer. A consistent association between post-
menopausal obesity and ER-positive/PR-positive tumors was identified in three of the 
four studies (one cohort and two case-control) that assessed this relationship (reviewed in 
Althuis et al. 2004). Furthermore, risk estimates increased incrementally with increasing 
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BMI and reached statistical significance in two of the studies, and the Iowa Women’s 
Health Study has also shown that post-menopausal obesity was associated with an 
increased risk for hormone receptor-positive breast cancer, regardless of ER, PR, or 
ER/PR joint status (Althuis 2004). Parity, or the number of times a woman carries a 
pregnancy to a viable gestational age, is another non-genetic factor that impacts a 
woman’s likelihood of developing breast cancer. The reduction in breast cancer risk 
associated with parity was more consistently observed for ER-positive than ER-negative 
tumors, and risk estimates ranged from 0.5-0.8, with the greatest reductions noted for 
multiparous women. Although the small size of several studies limits the statistical power 
of the analyses to find significant differences, the point estimates suggest that increasing 
parity may reduce the risk of ER positive breast cancers (Althuis 2004). Exogenous 
hormone usage via hormone replacement therapy or oral contraceptive use has modest 
evidence as an external risk factor in increasing one’s risk of developing breast cancer. 
Recent oral contraceptive use was more strongly associated with ER-negative tumors 
than ER-positive tumor subtypes in two the investigations examined (Althuis 2004). The 
Nurses’ Health Study did not find an increased risk for breast cancer among current 
users, but it did report a stronger association of past use of postmenopausal hormones 
with ER-positive tumors (Althuis 2004). Given the information presented above, the 
complex, heterogeneous nature of breast cancer gives the reader valuable insight into 
why this disease is not only so prevalent throughout the world but difficult to manage due 
to its variety of external influences. 
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B.) Malignant Progression 
Malignant progression of breast cancer and how said progression comes to 
fruition is a unique aspect of cancer in general. Cancer impacts the body at the most 
fundamental level by altering cells and their associated mechanisms. Normally, cell 
proliferation functions as a means of replacing dead or defective cells. The means by 
which these cells grow and divide are tightly regulated by many intracellular 
mechanisms. However, cancer cells escape the control of these regulators and proliferate 
uncontrollably. This phenotype is also associated with diminished cell death, invasion of 
surrounding tissues, and metastasis throughout the body using the vascular and lymph 
systems. Before cancer cells can metastasize, they form an abnormal mass of tissue called 
a tumor, or neoplasm. Most tumors grow as solid masses comprised of two distinct, 
interdependent compartments called the parenchyma and the stroma. The parenchyma 
consists of the neoplastic cells of the tumor while the stroma is connective tissue, blood 
vessels, etc. that provides tumors with nourishment and aids in the removal of waste 
products. Tumors experience temporally unrestricted growth into the surrounding tissues 
with the ability to grow in at least three different tissue compartments: the original 
compartment, the mesenchyme (tumor invasion), and a distant mesenchyme (tumor 
metastasis). Tumors are typically classified as cancerous once they invade the 
surrounding mesenchyme, which is characteristic of the transition from normal 
epithelium to cancer. 
Tumorigenesis is not an immediate change, but instead, it is the result of a multi-
step process in which cancer cells shift from a normal, benign phenotype to a malignant 
one. This process is a slow one that typically occurs over many years. In order to transit 
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from normal epithelium into cancer, breast cells undergo this multi-step process 
beginning with the change from normal tissue to intraductal hyperplasia, in which the 
cells still appear very close to normal. From there, cells become an intraductal 
hyperplasia with atypia, with cell shape becoming more irregular and distorted. After this 
stage, the tumor undergoes the transition into intraductal carcinoma in situ and is now 
classified as cancerous, even though it has yet to invade any new tissues.  Lastly, tumors 
become invasive cancers, and at this step, the tumors either invade the local mesenchyme 
or metastasize to other areas of the body. In order to describe how these metastases arise, 
one must address the complexities of the invasion-metastasis cascade. The answer to how 
cancer cells acquire the ability to complete the steps required to metastasize seems to 
depend on the fact that cancer cells appropriate complex biological programs that play 
roles in normal cell and organismic physiology (Weinberg 2008). In this instance, the 
specific normal biological process involves the epithelial-mesenchymal transition (EMT), 
which plays key roles in many steps of normal morphogenesis. Cells are required to 
undergo this transition because true epithelial cells are incapable of translocating to a 
distant region of the body, so cells are required to shed certain epithelial traits in favor of 
mesenchymal traits, which allow for locomotion and invasion of the extracellular matrix.  
The process of EMTs can be programmed by a variety of transcription factors 
(TFs) that are activated transiently in various stages of embryogenesis and throughout the 
embryo. The transient expression of these TFs indicates that cells will maintain their 
mesenchymal form while said transcription factors are active, but cells will revert to their 
ground state in the absence of these TFs. Although the brief description of EMT 
presented does not readily indicate the relevance to cancer cells, two key aspects of 
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carcinoma cells point to the relevance these embryonic programs and TFs have to tumor 
progression. First, many of the phenotypic traits of embryonic cells are recapitulated by 
aggressive carcinoma cells. Second, many of the embryonic TFs that are known to play 
critical roles in orchestrating EMTs during embryogenesis are expressed in a variety of 
human tumor cells. In fact, their expression is often correlated with aggressive tumor 
cell-associated traits (Weinberg 2008). During embryogenesis, the expression of various 
EMT-inducing TFs appears to occur in response to certain contextual signals that are 
released by nearby cells. It seems likely that the same type of heterotypic signals impinge 
on various carcinoma cells during the process of carcinoma progression. It also seems 
that, in general, none of these ligands is, on its own, capable of triggering EMT; instead, 
in many circumstances, they seem to act in coordination to provoke EMT in nearby-
carcinoma cells. However, the rules that define these interactions are still unexplored 
(Weinberg 2008). As for the context of carcinoma pathogenesis, it is likely that these 
heterotypic signals are released by mesenchymal cells that form the tumor-associated 
stroma. These mesenchymal cells have a different origin than the carcinoma cells that 
became mesenchymal via EMT. These stromal cells are recruited either from the stroma 
of the tissue in which the tumor arises or, alternatively, from the bone marrow, which 
appears to generate a number of distinct types of mesenchymal progenitor cells that are 
released into the circulation and become available for local recruitment by carcinoma 
cells. Such cells appear to enter into the tumor-associated stroma and thereafter 
differentiate into a variety of mesenchymal cell types, including myofibroblasts and 
endothelial cells. In fact, the stroma of most carcinomas is assembled from a variety of 
mesenchymal cell types whose precise origins are still quite unclear (Weinberg 2008). 
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The fact that heterotypic signals may induce an EMT in carcinoma cells reveals another 
important aspect of malignant progression: these cells do not need to undergo additional 
genetic changes in order to acquire the cellular phenotypes associated with high-grade 
malignancy. Instead, when confronted with an appropriate mix of contextual signals, 
primary carcinoma cells will develop such phenotypes without suffering additional 
mutations (Weinberg 2008). The fact that carcinoma cells that undergo an EMT adopt 
mesenchymal phenotypes and invade into the tumor stroma and then into adjacent normal 
tissues creates an experimental difficulty, since these invading neoplastic cells are, at 
least superficially, indistinguishable from the true mesenchymal cells that surround them 
in the tumor stroma and, later on during the course of invasion, in the stroma of normal 
tissues lying outside the initial margins of tumors. This complication has caused some 
pathologists to dismiss the EMT as a laboratory artifact (Weinberg 2008). It seems likely, 
however, that this controversy will be settled, sooner or later, because of two factors. 
First, it is probably the case that most carcinoma cells undergoing an EMT do so 
incompletely, i.e. by partially shutting down epithelial markers (such as E-cadherin and 
cytokeratins) while acquiring mesenchymal markers (such as N-cadherin, vimentin and 
fibronectin). Accordingly, future attempts at finding cells co-expressing both epithelial 
and mesenchymal markers are likely to reveal the invading neoplastic cells hiding among 
the true mesenchymal cells in the stroma (Weinberg 2008). A second fact is likely to help 
reveal otherwise occult cancer cells that have undergone an EMT: carcinoma cells that 
have passed through an EMT express certain markers that appear not to be expressed by 
true mesenchymal cells. These two factors should reveal the elusive wolves hiding in 
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sheep's clothing—the invasive carcinoma cells present in small nests and large aggregates 
in the otherwise-normal tissues of carcinoma patients (Weinberg 2008).  
Given current knowledge, it is plausible that the expression of one of these TFs 
should enable a primary tumor cell to invade locally, intravasate, survive in the 
circulation, extravasate and survive for a limited period of time in the parenchyma of a 
foreign tissue in which it has landed. The subsequent fate of such a disseminated cell is 
less clear, however. Thus, a breast cancer cell landing in the brain, the bone marrow, or 
the liver must confront an array of extracellular matrix components, signaling molecules 
and stromal cell types to which it is, at least initially, poorly adapted (Weinberg 2008). 
This lack of instantaneous compatibility between newly arrived cancer cells and their 
newfound homes is likely to explain the very low success rate of the last step of the 
invasion–metastasis cascade—the growth of a micrometastasis into a macroscopic 
metastasis that is, as mentioned, termed colonization. It is apparent that only a small 
number of micrometastases out of the thousands that are initially seeded ever succeed in 
growing into a macroscopic metastasis. It also seems apparent that colonization is not a 
problem that is readily addressed by the multiple traits programmed by an EMT-inducing 
TF (Weinberg 2008). To be sure, the increased resistance to apoptosis associated with an 
EMT program should increase the survival of the cells within a micrometastasis. This 
acquired trait does not, however, deal with the fact that these cells are otherwise 
maladapted to the foreign microenvironment of the tissue in which they have landed 
(Weinberg 2008).  
Mechanisms of the sort depicted here, involving components of the EMT 
program, may ultimately serve to explain how carcinoma cells are able to leave the 
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primary tumor and ultimately arrive at distant anatomical sites. It is unclear at present 
whether aggressive tumors arising from different embryonic cell lineages, specifically 
hematopoietic, neuroectodermal and mesenchymal tumors, deploy the same set of 
mechanisms or whether their metastatic dissemination depends on an entirely different 
set of factors and molecular mechanisms. Indeed, at present, it remains possible that the 
motility and invasiveness of some carcinomas derives from mechanisms that have 
nothing whatsoever to do with the EMT, although it is suspected otherwise (Weinberg 
2008). 
C.) Diagnosis/Treatment 
It is important to consider how cancer is not only diagnosed but also treated once 
a diagnosis has been made. An important method in diagnosing and treating breast cancer 
is screening. Screening is considered the one of the most important public health 
strategies to reduce mortality from breast cancer (Libson 2014). For example, along with 
increased rates of screening, the rates of incidence of early stage cancers has increased 
dramatically, and in turn, a reduction in mortality has been observed as well (Libson 
2014).  Breast cancer screening can be performed through a plethora of tests with ranging 
specificity, but only four will be focused on: mammography, MRI, breast biopsy, and 
HER-2/neu detection assay. Mammography has been the hallmark test for breast cancer 
screening for years. Mammography is the use of X-rays in order to capture a picture of 
the breast, and over the years, digital mammography has replaced conventional (film) 
mammography in some screening services. Digital provides advantages over 
conventional (film) mammography through the use of computer-aided detection and 
algorithm-based computer programs that alert the radiologist to possible abnormalities. 
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With that being said, mammography should not be frequently used due to potential 
radiation risk (Nounou 2015). Magnetic resonance imaging (MRI) is another method 
used in the diagnosis of breast cancer. While not a method routinely used in conventional 
diagnosis, MRI is considered a useful adjunct to diagnostic mammography by the 
National Comprehensive Cancer Network, if needed in certain situations (Nounou 2015). 
The MRI method is valuable in the screening of selected high-risk patients, patients in 
whom breast augmentation prevents effective screening mammography, or patients with 
equivocal findings on other imaging modalities (Shah 2014). However, due to its poor 
selectivity and dependence on contrast media, MRI is typically only used in a 
supplementary role in the diagnosis of breast cancer. Although mammography and MRI 
are useful in diagnosing breast cancer, the only definitive method for diagnosing breast 
cancer is with a breast biopsy. To ensure the elimination of false negative results and 
increase diagnostic accuracy, clinical breast examination, breast imaging, and breast 
biopsy are performed simultaneously. Needle biopsies are the method used in diagnosis, 
and they consist of two methods: fine needle aspiration cytology (FNAC) and core needle 
biopsy (CNB). The FNAC method is the least invasive type, using a thin hollow needle to 
extract cells from the suspicious lesion. The CNB method used a larger needle and 
removes a small cylinder of tissue about the size of a grain of rice from the lesion, with 
about three to five cores being removed. In both methods, samples are sent to the 
laboratory in order to determine malignancy (Nounou 2015). One of the last, more novel 
methods used to diagnose breast cancer is HER-2/neu detection assay. This assay is an 
immunohistochemistry technique (IHC) that uses antibodies as a tool to detect protein 
expression. Monoclonal or polyclonal antibodies complementary to the antigen of interest 
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are labeled with a marker, allowing detection of the antibodies bound to regions of 
protein expression in a tissue sample (Nounou 2015).  
After the diagnosis of an individual has been reached, determining the method of 
treatment becomes the next issue. Prognostic and predictive factors aid in diagnosing and 
determining the treatment protocol for breast cancer patients, which makes them valuable 
tools. Prognostic factors are clinical or biological characteristics that are objectively 
measurable and provide information on the likely outcome of the cancer disease. 
Predictive factors, on the other hand, are clinical or biological characteristics that provide 
information on likely benefit from a specific treatment. For example, status of the lymph 
nodes is one of the single most important prognostic factors, and overall survival 
significantly decreases as the number of affected lymph nodes increases.  
Tumor size is the second most valuable prognostic factor, and a larger size tumor 
is equated with a worse prognosis (Libson 2014). Even though estrogen receptor (ER) 
and progesterone (PR) receptor status are considered weak prognostic indicators, they are 
the strongest predictive factors for response to endocrine therapy, and as such, ER and PR 
assays should be performed on all breast cancers (Shah 2014). Another important 
prognostic factor for breast cancer treatment is the HER-2 protein expression and gene 
amplification. The HER-2 proto-oncogene encodes for a transmembrane tyrosine kinase 
growth receptor. The overexpression of HER-2 is a prognostic factor for outcomes in 
both node-negative and node-positive patients, and furthermore, it is also a predictive 
factor for response to certain therapies that target HER-2 receptors (Shah 2014).  
After the final diagnosis and analysis of all prognostic and predictive factors, 
treatment options can finally be considered. The main types of treatment for breast cancer 
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are surgery, endocrine therapy, radiation therapy, and chemotherapy. In the case of 
surgery, it is always followed by adjuvant therapy in order to ensure full recovery and 
minimalize the risk of metastases. Because certain cancer cells may not be seen during 
surgery, adjuvant therapy works to minimalize the risk of local recurrence of cancer cells 
as well. Mastectomy is the go-to surgical method, and approximately 30%–40% of breast 
cancer patients in the United States are candidates for mastectomy. There are different 
levels of invasiveness to mastectomies. A total mastectomy (TM) involves the complete 
removal of the breast. Skin-sparing mastectomy (SSM) is similar to TM, but the 
procedure spares as much skin as possible. Nipple-saving mastectomy (NSM) is similar 
to SSM, but in this instance, the areola or nipple is saved as well. Lastly, the most 
invasive mastectomy is radical mastectomy (RM). This version involves the complete 
removal of the pectoralis muscles and level III axillary nodes (Shah 2014).  
Alternatively, endocrine therapy (ET) is rather straightforward in that its goal is 
either to balance or block hormones in cancer cells. ET is indicated in all patients with 
detectable ER expression, and the choice of medication is determined by the patient’s 
menopausal status (Nounou 2015). Radiation therapy (RT) is a process in which cancer 
cells are directly exposed to high levels of radiation, but there are significant side effects 
of RT on the skin. These include decreased sensation in breast tissue, skin problems in 
treated area, and at the end, the skin may become moist and weepy (Nounou 2015). 
Lastly, chemotherapy (CT) is simply the use of chemical agents in treating breast cancer. 
The benefit from CT is more pronounced in ER-negative tumors, and it is recommended 
in the vast majority of triple-negative breast cancer (TNBC), HER-2 positive cancers, and 
in high-risk luminal tumors. Overall, CT regimens based anthracyclines and taxanes 
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reduce breast cancer mortality by about one-third. CT is also used in neoadjuvant therapy 
in order to reduce tumor size before surgery when the tumor is inoperable due to size. 
Although CT is a hallmark treatment for breast cancer, it has serious negative health 
effects in addition to side effects such as hair loss, neutropenia, and depressed immunity 
(Nounou 2015). 
Because of the significant adverse effects of treatments like chemotherapy and 
radiation therapy, the development of selective drug delivery systems and novel treatment 
carriers have become something of a necessity. These drug delivery systems are an 
important approach with tremendous potential in overcoming problems associated with 
systemic toxicity. Targeted drug delivery systems for antitumor drugs have demonstrated 
great potential to lower cytotoxicity associated with typical treatments and increase the 
associated therapeutic effects. Targeting can occur through either passive or active 
targeting (Nounou 2015). Passive targeting relies on taking advantage of the chemical 
and physical properties of cancer tissue. Cancer tissues have large fenestrations in the 
cancer vasculature resulting from imbalance angiogenesis, which are wide enough to let 
large nanoparticles pass and accumulate within the cancer tissue. This vascular 
permeability is referred to as enhanced permeability and retention effect (EPR). This EPR 
effect is the main concept of passive targeting for tumor selective delivery of 
macromolecular drugs. However, the EPR effect is frequently inhomogeneous in tumor 
tissue, and this heterogeneity of the EPR effect may reduce the tumor delivery of 
macromolecular drugs (Nounou 2015). Active targeting is the other aspect of targeted 
drug delivery, as it was proposed for its improved targeting efficacy. Active targeting 
involves a targeting moiety such as a protein or antibody that is either conjugated to the 
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nanoparticulate system or the drug moiety directly targeting specific receptors on the 
cancer cell. An overexpression of receptors or in antigens in cancer acts as a potential 
target to achieve efficient drug uptake via receptor-mediated endocytosis (Nounou et al. 
2015). With modern medicine and science rapidly advancing, the increasing number of 
possibilities and combinations that can be used to create effective treatment methods 
should provide breast cancer patients with optimism in knowing progress is being made.  
D.) Drug Resistance 
Quite possibly the biggest obstacle facing scientists today is the development of 
resistance to anticancer drugs by cancer cells. With the development of safe and effective 
new drugs taking years, scientists and physicians are beginning to run out of options for 
treating individuals with breast cancer. Cancer cells exhibit the incredible ability to 
continuously adapt to new drugs and treatment regimens, and finding ways to circumvent 
this resistance is markedly difficult. A major component of intrinsic drug resistance in 
cancer cells involves tumor heterogeneity. Intra-tumor heterogeneity can be observed at 
many different levels of cancer and may be assignable to a number of different factors 
that primarily occur at the cellular level. Genomic instability creates a significant 
intercellular genetic heterogeneity in cancer, and genotypic changes that can arise from 
such instability and affect tumor heterogeneity include: mutations, gene amplifications, 
deletions, and chromosomal rearrangements, just to name a few. These factors can 
change, increase, or diminish gene products, which are directly involved in the generation 
of drug resistance and poor prognosis (Mansoori et al. 2017). The tumor 
microenvironment is also thought to play a key role in the generation of resistance against 
anti-cancer drugs. The tumor microenvironment involves stromal cells, extracellular 
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matrix, and several soluble factors, such as cytokines and growth factors. Tumor-tumor 
cell communication, tumor-stromal cell communication, as well as tumor-ECM interface, 
all contribute to direct cell interaction mediated by drug resistance. Moreover, growth 
factors and cytokines produced in the tumor microenvironment provide additional signals 
for tumor cell growth and survival (Mansoori 2017).  
Cancer stem cells present yet another pivotal element in the production of drug 
resistance in cancer cells. Although chemotherapy impairs a tremendous number of cells 
in tumors, it is understood that chemotherapeutic agents are removed from cancer stem 
cells through special mechanisms. For instance, with overexpression of the ATP-binding 
cassette, drug transporters such as ABCB1 and ABCG2 have been shown to keep cancer 
stem cells away from chemotherapeutic agents (Monsoori 2017). In addition, cancer stem 
cells share common traits with normal stem cells, such as active DNA repair capacity, 
resistance to drugs and toxins, resistance to apoptosis, and hypoxic stability. With these 
mentioned features, these cells remain stable in patients who appear to be recovering or 
can metastasize to distant organs and cause cancer recurrence (Mansoori 2017). Due to 
the nature of cancer stem cells, finding and targeting populations of them in tumors could  
have a major impact in decreasing tumor resistance. Multi-drug resistance (MDR) in 
cancer chemotherapy has been pointed out as the ability of cancer cells to survive against 
a wide range of anti-cancer drugs. MDR works by not only increasing the amount of drug 
released outside of the cell but also reducing the amount of chemotherapy agent absorbed 
by the cell. Cancer cells increase the amount of drug released outside of the cell by using 
a family of ATP-dependent transporters that are involved in transporting nutrients and 
other molecules across the membrane. These ABC transporters are composed of two 
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cytoplasmic domains that bind to ATP known as the ATP binding cassette (ABC) and 
two transmembrane domains. The P-glycoprotein (PGP), which is an ABC family 
member, is a multidrug membrane transporter that is normally known as a pump for 
moving chloride out of cells, but it can also bind to a variety of chemotherapy agents. 
Following the binding of these agents, ATP is hydrolyzed and the structure of P-gp is 
altered, and as a result, the agent is released into the extracellular space. After a second 
ATP molecule is hydrolyzed, the transporter is able to return to its original structure and 
is ready to release the drug outside of the cell (Mansoori 2017). Besides increasing the 
amount of drug released outside of the cell, cancer cells are also able to reduce the 
amount of drug absorbed. This can occur by reducing the tendency of drugs to bind to 
receptors or by reducing the number of receptors. Some agents require specific 
transporters in order to enter cells, and mutations in these transports can inhibit them, 
thereby reducing the absorption of the drug (Monsoori 2017).  
Finally, one of the most important mechanisms in altering drug resistance comes 
in the form of epigenetic alterations. These alterations occur through methylation of DNA 
and histone alterations. DNA methylation is a major epigenetic phenomenon occurring 
when cytosine is methylated at the 5’ carbon in the CpG islands (an upstream of 
promoters), but it can occur throughout the genome in other positions as well. For 
example, tumor suppressor genes are often silenced by methylation of their promoters, 
yet hyper-methylation of oncogene promoters induces transcription. Demethylation of the 
multi-drug resistance gene (MDR1) leads to the acquisition of the multi-drug resistant 
phenotype and reduces the accumulation of anti-tumor drug in cells (Monsoori 2017). As 
scientists and physicians scramble to find new and innovate ways to combat cancer drug 
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resistance, only time will tell whether their labors will bear the fruit needed to accomplish 
such a daunting task. 
 
2.) Fatty Acid Synthesis and Lipid Metabolism in Breast Cancer 
Even though cancers are hugely diverse in classification and etiology, cancerous 
cells predominantly share the attribute of metabolic abnormalities. In cancer cell 
metabolism, the most commonly thought of abnormality pertains to the Warburg effect. 
The Warburg effect describes glucose metabolism within cancer cells, in which 
glycolysis is decoupled from pyruvate oxidation, and in doing so, carbon from glucose is 
used to build other molecules instead of completely oxidizing them to carbon dioxide 
(Currie et al. 2013). Because of this, cancer cells are unable to produce the maximum 
amount of ATP possible via mitochondrial respiration, despite high oxygen availability. 
During normal cellular metabolism in the presence of oxygen, glucose molecules undergo 
glycolysis in order to form pyruvate, and after pyruvate enters the mitochondria, it is 
oxidized to acetyl-CoA, which then enters the Krebs cycle to produce the reducing 
equivalents needed for oxidative phosphorylation. However, cells in oxygen limiting 
environments ferment pyruvate to lactate. Normal cells, however, preferentially use 
oxidative phosphorylation because it yields ~36 ATP molecules, whereas anaerobic 
glycolysis produces two ATP molecules. The Warburg effect is the use of fermentation in 
aerobic conditions and is characterized by an increase in glucose uptake and 
consumption, a decrease in the rate of oxidative phosphorylation, and the production of 
lactate (Currie et al. 2013). 
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Alterations in fatty acid (FA) metabolism in cancer cells have received less 
attention over the years but are increasingly being recognized, especially in breast 
cancers due to breast tissues’ high adipose content. Fatty acids (FAs) are molecules that 
consist of a terminal carboxyl group and a hydrocarbon chain that can be either saturated 
or unsaturated. Fatty acids are pivotal for energy storage, membrane proliferation, and the 
generation of numerous signaling molecules in the body. Fatty acid/lipid metabolism is 
another aspect of normal cell metabolism that is altered in cancer cells and other rapidly 
proliferating cells. In cancer cells, carbon is diverted from energy production to FAs for 
biosynthesis of membranes and signaling molecules, and all lipids are derived in part 
from acetyl-CoA with many containing FAs. The building blocks for fatty acids can 
come from either exogenous sources or de novo synthesis. While most normal cells 
prefer exogenous sources, tumors synthesize FAs de novo and often exhibit a shift toward 
FA synthesis (Currie et al. 2013). Within cells, fatty acids have many different fates, 
including being incorporated into membrane, storage, or signaling lipids, or oxidized to 
carbon dioxide as an energy source.   
Fatty acid synthesis is an anabolic process that starts from the conversion of 
acetyl CoA to malonyl CoA by acetyl CoA carboxylase. Malonyl CoA is then committed 
to fatty acid synthesis (FAS) and is involved in the elongation of fatty acids through fatty 
acid synthase (FASN). Additional modifications of fatty acids can be carried out by 
elongases and desaturases (Arkaitz et al. 2013). The fatty acids produced in cancer cells 
play an important role in cell invasion and metastasis. Many of signaling molecules 
composed of fatty acids promote cell migration and metastasis, and one of the ways cells 
accomplish this is through induction of EMT by transforming growth factor-β (TGF- β) 
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(Röhrig et al. 2016). The induction of EMT requires complex remodeling of cellular lipid 
composition to facilitate changes in membrane fluidity required for cell migration. 
Treatment of breast cancer cells with compounds that disrupt a gene expression signature 
associated with EMT reduced membrane fluidity and blocked migration and lung 
metastasis formation after tail vein injection in mice (Röhrig et al. 2016). Interestingly, 
the effect on membrane fluidity was abolished after addition of oleic acid, which disrupts 
the dense packing of saturated acyl chains. Oleic acid also restored metastasis formation 
in vivo, suggesting that monounsaturated FAs promote this crucial step during tumor 
progression (Röhrig et al. 2016). 
The alterations in lipid metabolism and fatty acid synthesis in cancer cells are also 
due to genetic aspects of cancer cells. The transcription of genes involved in fatty acid 
synthesis is regulated by the sterol regulatory element-binding protein 1 (SREBP-1) 
transcription factor, which regulates not only the enzymes needed to convert acetyl-CoA 
into fatty acids but also the enzymes of pentose phosphate pathway and the pathways 
required to convert acetate and glutamine into acetyl-CoA. SREBP-1 also not only 
regulates cholesterol biosynthesis but genes encoding proteins that catalyze or facilitate 
fatty acid synthesis (DeBerardinis et al. 2016). Both fatty acids and lipids can also be 
acquired from the extracellular space to supply membrane biosynthesis. The process of 
PI3K signaling activates fatty acid uptake and suppresses fatty acid oxidation, thereby 
maximizing lipogenesis in proliferating cells under the control of growth factors. Lipid 
uptake becomes extremely important under metabolic stress, when the ability to meet 
oncogene-driven demands for biosynthesis is compromised. The ability to scavenge 
lysophospholipids (lipid intermediates containing a glycerophosphate backbone with one 
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acyl chain) is a trait required for maximal cancer cell growth during hypoxia, as de novo 
fatty acid synthesis from glucose is suppressed under hypoxic conditions (DeBerardinis 
et al. 2016). Furthermore, in cancer cells with constitutive mTORC1 signaling, hypoxia 
induces a state of dependence on access to extracellular desaturated fatty acids to 
maintain endoplasmic reticulum integrity in support of protein 
biosynthesis (DeBerardinis et al. 2016). Although cancer cells activate de novo FA 
synthesis, they also require the uptake of essential FAs. For example, α-linoleic acid and 
linoleic acid carry double bonds beyond position 9 of the acyl chain; these cannot be 
synthesized by humans and have to be provided by diet. Essential FAs are important for 
multiple cellular functions, including the synthesis of signaling lipids and 
phosphoglyceride species found in lipid rafts (Röhrig et al. 2016). Evidence for the 
importance of essential FAs for tumor growth comes from a recent study that investigated 
lipid composition of prostate tumors using Raman spectroscopy. This study found that 
aggressive prostate cancers showed high numbers of lipid droplets containing cholesteryl 
esters (CEs). This was due to increased expression of sterol O-acyltransferase 1 (SOAT1, 
also known as ACAT1), which catalyzes the conversion of free cholesterol into CE and 
its subsequent storage in lipid droplets. Through this mechanism, cancer cells prevent the 
accumulation of free cholesterol, which would normally block expression of the LDLR 
through sterol-dependent inhibition of SREBP (Röhrig et al. 2016). 
With the importance of lipid metabolism and fatty acid synthesis in breast and 
other cancers having been established, targets and potential treatment options that can 
effectively limit cancer cell access to lipids and potentially inhibit their rate of metastasis. 
This goal could be achieved through several different methods: blocking fatty acid 
	22	
synthesis, increasing fatty acid oxidation, diverting fatty acids to storage, or decreasing 
fatty acid release from storage (Currie et al. 2013). Blocking fatty acid synthesis is 
essentially the most effective and simplest method to reduce fatty acid levels in cancer 
cells. ATP citrate lyase, acetyl-CoA carboxylase, fatty acid synthase, and acyl-CoA 
synthetases are all enzymes that would decrease fatty acid availability if inhibited. More 
importantly, many of the inhibitors for these enzymes have minimal effects on non-
cancer cells, increasing the clinical significance of this method. Another method of 
reducing fatty acid levels would be to reduce expression of the enzymes at the 
transcription level. Inhibiting SREBP, the master transcriptional regulator of FA 
synthesis, in cancer cells could decrease FA synthesis gene expression and possibly 
prevent cancer cell proliferation (Currie et al. 2013). The second method to limiting fatty 
acid access is increasing the degradation of fatty acids. The FAs are broken down by 
mitochondrial β-oxidation. In this method, fatty acids are repeatedly cleaved to produce 
acetyl-CoA that feeds into the Krebs cycle. This method is beneficial in theory, but data 
from experiments testing this theory has produced mixed results (Currie et al. 2013). The 
third method involves diverting fatty acids to storage. Most cells store FAs as TGs in 
lipid droplets (LDs), an organelle whose major function is lipid storage, and while 
increased number of LDs have been reported in many cancer cells, their role in cancer is 
still unclear. The last method to mediate the amount of fatty acids cancer cells can access 
is blocking fatty acid release from storage. Once stored, fatty acids can be released for 
use by specific lipases, by preventing lipolysis, the available FA pool available for cancer 
cells might be decreased, especially since FAs derived from lipolysis can also serve as 
precursors for important signaling lipids (Currie et al. 2013). 
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Although the importance of lipid synthesis for the proliferation and survival of 
cancer cells is well established, much less is known about the role of β-oxidation in 
cancer. However, several reports have demonstrated that cancer cells require β-oxidation, 
particularly under stress conditions (reviewed in Röhrig et al. 2016). For example, the 
brain-specific carnitine palmitoyltransferase 1C (CPT1C) is induced by adenosine 
monophosphate-activated protein kinase (AMPK) in response to metabolic stress in 
cancer cells to support energy generation when glycolysis is inhibited by rapamycin 
treatment. More recently, it was shown that β-oxidation is an important bioenergetics 
pathway in triple-negative breast cancer and is required for the activation of proto-
oncogene tyrosine-kinase Src (Src). Targeting this pathway may limit the metabolic 
flexibility of cancer cells and should be considered as a strategy for cancer treatment 
(Röhrig et al. 2016). The oxidative degradation of fatty acids produced in cancer cells 
also serves as a vital source of NADPH within these cells. The NADPH exerts two main 
functions within cells. It provides redox power to counteract oxidative stress, which has 
proved to be crucial for cancer cell survival in conditions of metabolic stress. On the 
other hand, it is a coenzyme for anabolic enzymes, and thus, it is key for the generation of 
new building blocks to sustain cell growth and proliferation (Arkaitz et al. 2013).  
Fatty acid synthesis and lipid metabolism in cancer cells play a crucial role in the 
pathogenesis of tumors and metastatic potential of cancer cells. Furthermore, both retain 
crucial roles in oxidative stress and protein carbonylation as well, and the scope of how 
lipid metabolism and fatty acid synthesis affect both processes is both complex and vast.  
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3.) Oxidative Stress and Protein Carbonylation 
The generation of reactive oxygen species (ROS) and nitrogen species 
unrestrained, and subsequent oxidative stress, has been implicated in the pathogenesis of 
many diseases, as well as aging in general (Lee et al. 2017). Oxidative stress can be 
broadly defined as an imbalance between oxidants and antioxidants in favor of the 
oxidants, which can potentially lead to damage. If the level of reactive species is high and 
overcomes the antioxidant defense mechanisms of the body, oxidative damage can occur 
to lipids, proteins, or directly to DNA. This DNA damage has been hypothesized to play 
an important role in the initiation of carcinogenesis. The mechanisms surrounding 
oxidative stress are involved in the activation of cell signaling pathways, including tumor 
proliferation, increased tumor cell migration, and increased tumor cell proangiogenic 
factors, and play a key role in apoptosis, mechanisms that can impact both cancer 
progression and metastasis. Furthermore, reactive oxygen species and the resulting high 
oxidative stress are key characteristics of malignant tumors (Lee et al. 2017). 
Oxidative stress is not limited to one mechanism and may occur via more than 
one pathway. In addition, oxygen radicals are not only generated in the mitochondria but 
also by neutrophils and macrophages that produce ROS via a plasma membrane bound 
nicotinamide adenine dinucleotide phosphate, reduced form (NADPH)-oxidase. The 
radicals are generated for cell killing and bactericidal activities, but the NADPH-oxidase 
is not exclusive to these cells. A panel of human tumor cell lines was shown to produce 
large quantities of hydrogen peroxide in vitro (Brown and Bicknell 2001). The hydrogen 
peroxide production was prevented by diphenyleneiodonium, which is an inhibitor of the 
flavoprotein component of the NADPH-oxidase. Tumor cells may overproduce ROS 
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because the NADPH-oxidase is regulated by the GTPase Rac1, which is itself 
downstream of the proto-oncogene Ras (Brown and Bicknell 2001). Carcinoma cell 
oxidative stress can also be induced by thymidine phosphorylase, an enzyme that is 
overexpressed in the majority of breast carcinomas. Thymidine phosphorylase catabolizes 
thymidine to thymine and 2-deoxy-D-ribose-1-phosphate; the latter is a very powerful 
reducing sugar that rapidly glycates proteins, generating oxygen radicals within the 
carcinoma cell. Thymidine phosphorylase activity induces carcinoma cell oxidative stress 
in vitro (Brown and Bicknell 2001), and the frequent upregulation of thymidine 
phosphorylase in human breast tumors suggests that this may be an important cause of 
oxidative stress in breast cancer. Oxidative stress within breast carcinoma may also be 
caused by a breast specific mechanism, namely the metabolism of estrogenic hormones 
by lactoperoxidase. Lactoperoxidase, an enzyme that is produced within the mammary 
gland, catalyzes the one-electron oxidation of 17 β-estradiol to a reactive phenoxyl 
radical (Brown and Bicknell 2001). Inadequate vasculature within a tumor also possesses 
the ability to induce oxidative stress in cancer cells. As a breast tumor rapidly outgrows 
its blood supply, the cells become deprived of glucose and undergo hypoxia. This glucose 
deprivation was shown to rapidly induce cellular oxidative stress within the MCF-7 cell 
line, but it did not in any of the non-transformed cell lines. This may be because glucose 
deprivation reduces intracellular pyruvate within the breast carcinoma cell, which 
prevents the decomposition of endogenous oxygen radicals (Brown and Bicknell 2001). 
Infiltration of macrophages in the tumor cells can also induce oxidative stress, as tumor-
associated macrophages deliver sublethal oxidative stress to murine mammary tumor 
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cells. In addition, tumor necrosis factor-α is secreted by tumor-associated macrophages 
and induces cellular oxidative stress (Brown and Bicknell 2001).  
The consequences associated with oxidative stress within carcinoma cells are 
numerous as well. Oxygen radicals are powerful DNA damaging agents, and as a result, 
ROS cause strand breaks, alterations in guanine and thymine bases, and sister chromatid 
exchanges. These effects may inactivate additional tumor suppressor genes within tumor 
cells or further increase expression of proto-oncogenes. Therefore, persistent genomic 
instability due to oxidative stress will increase the malignant capacity of the tumor. 
Sublethal oxidative stress, similar to that administered by macrophages, promotes cell 
proliferation in vitro, with both superoxide and hydrogen peroxide stimulating growth 
(Brown and Bicknell 2001). Proliferation in response to hydrogen peroxide may be due to 
the activation of mitogen-activated protein kinases (MAPKs). When HeLa cells are 
treated with hydrogen peroxide they undergo a sustained activation of all three MAPK 
pathways: extracellular signal related protein kinase, c-Jun amino-terminal kinase/stress-
activated protein kinase, and p38 (Brown and Bicknell 2001). Hyperphosphorylation of 
c-Jun by oxidative stress activates activator protein-1 in MCF-7 breast carcinoma cells, a 
response that stimulates proliferation, and multidrug-resistant human breast carcinoma 
cells rapidly activate extracellular signal related protein kinase-2 when stressed by 
glucose deprivation (Brown and Bicknell 2001). In addition, ROS may trigger mitosis via 
MAPK independent mechanisms. Oncogenic Ras causes ROS production by activating 
Rac1 and the NADPH-oxidase. In Ras-transformed human fibroblasts, ROS drive cell 
cycle progression without the activation of MAPK pathways (Brown and Bicknell 2001). 
Severe oxidative stress leads to apoptosis within cells, cancerous or otherwise. 
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Conversely, persistent oxidative stress at sublethal levels may lead to acquired resistance 
against apoptotic mechanisms within cancer cells. The induction of cell death by ROS is 
dependent upon p53. Constitutive oxidative stress within breast carcinoma cells may 
therefore accelerate the selection of p53 knockout tumor cell clones, which have an 
apoptosis resistant phenotype (Brown and Bicknell 2001). Persistent oxidative stress may 
also cause adaptive responses within the tumor cell that confer resistance to apoptosis. 
The thiol antioxidant thioredoxin and metallothionein are rapidly upregulated in response 
to oxidative stress, and the antioxidants malondialdehyde, superoxide dismutase, 
glutathione peroxidase and catalase show increased expression or activity in breast tumor 
tissue as compared with normal controls (Brown and Bicknell 2001). An upregulation of 
anti-ROS defenses in cancer cells may explain why tumor cell lines in vitro are extremely 
resistant to cytolysis by hydrogen peroxide. In addition, antiapoptotic Akt (protein kinase 
B) is activated by hydrogen peroxide (Brown and Bicknell 2001). The antiapoptotic 
response that can develop in response to chronic oxidative stress may have severe 
implications for anticancer therapy techniques. This is because many chemotherapeutic 
agents rely on the production of ROS within tumor cells to induce apoptotic mechanisms, 
but if tumor cells develop a resistance to these mechanisms, chemotherapy drugs have no 
method to operate, making them practically useless. 
One of the final consequences of oxidative stress is an increased supply of blood 
to tumor cells and the increased risk of metastasis associated with this increased blood 
supply. Oxygen radicals increase tumor cell production of the angiogenic factors IL-8 
and vascular endothelial growth factor (VEGF). Tumor cell oxidative stress also 
promotes secretion of the matrix metalloproteinase-1 (MMP-1), a collagenase that aids 
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vessel growth within the tumor microenvironment (Brown and Bicknell 2001). Oxidative 
stress can, therefore, cause angiogenesis within breast carcinoma. Hypoxia and oxidative 
stress may be found together within the tumor, and VEGF production within oxidatively 
stressed breast carcinomas may be augmented by synergy between oxygen radicals and 
tumor hypoxia. Levels of the hypoxia-inducible factor-1 (HIF-1) may be increased by 
oxygen radicals, implying that oxidatively stressed carcinoma cells might show increased 
HIF-1 induction during hypoxia and therefore produce more VEGF (Brown and Bicknell 
2001). Oxidative stress is also thought to increase the blood supply to breast carcinoma 
by triggering vasodilatation. Hydrogen peroxide induces inducible nitric oxide synthase 
(NOS) in cytokine stimulated rat pleural mesothelial cells, raising the possibility that 
oxidatively stressed breast tumor cells might show increased expression of inducible 
NOS (Brown and Bicknell 2001). The nitric oxide produced would activate cGMP within 
nearby smooth muscle cells, leading to vasodilatation. Vasodilatation could also be 
triggered by carbon monoxide, because oxidative stress powerfully induces heme 
oxygenase-1, which degrades heme to biliverdin and carbon monoxide. Carbon 
monoxide, like nitric oxide, activates cGMP (Brown and Bicknell 2001). The increased 
angiogenesis within the breast tumor microenvironment also increases the risk of blood-
borne metastasis. Angiogenesis may promote lymphatic dissemination, a common 
occurrence in breast carcinoma, by elevating tumor interstitial pressure (Brown and 
Bicknell 2001). However, these are not the only mechanisms by which oxidative stress 
can aid tumor spread. Oxygen radicals may potentially augment tumor cell migration, 
increasing the risk of invasion and metastasis. The p38 MAPK is activated by oxidative 
stress, and the phosphorylation of heat shock protein-27 by p38 MAPK induces changes 
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in actin dynamics. Phosphorylated heat shock protein-27 promotes the migration of 
MDA-MB-231 breast cancer cells on laminin-5 in vitro (Brown and Bicknell 2001). As 
noted earlier, Rac1 can activate the NADPH-oxidase in tumor cells, causing superoxide 
production, and ROS mediate the role of Rac1 in actin cytoskeleton reorganization 
(Brown and Bicknell 2001). Oxidative stress within breast tumors may also facilitate 
invasion and metastasis by activating MMPs and inhibiting protease inhibitors. The 
MMP-2 is a gelatinase that is believed to play a major role in breast cancer invasion and 
metastasis. High levels of MMP-2 correlate with poor prognosis in breast cancer patients 
and active MMP-2 is detected more frequently in malignant than in benign breast tumors. 
ROS activate MMP-2, possibly by the reaction of oxygen radicals with thiol groups 
within MMP-2 (Brown and Bicknell 2001). Protease inhibitors, such as α1-proteinase 
inhibitor and plasminogen activator inhibitor, may be inactivated by oxidation of 
methionine residues at their active sites. This facilitates the activity of various proteases, 
increasing invasion and the likelihood of metastasis. For example, plasminogen activator 
is believed to play a role in metastasis (Brown and Bicknell 2001). Murine mammary 
carcinoma cells that are exposed to sublethal oxidative stress exhibit decreased 
attachment to immobilized laminin and fibronectin. Reduced tumor cell adhesion to 
basement membrane components increases the probability that the cells will detach and 
enter the blood vessels or lymphatic system (Brown and Bicknell 2001). In addition, 
treatment of these cells with hydrogen peroxide, before intravenous injection into mice, 
enhanced lung metastasis formation. This implies that oxidative stress may aid the 
seeding of metastatic tumor cells. Finally, ROS within the tumor microenvironment may 
promote metastasis by increasing vascular permeability, either by direct damage to 
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endothelial cells or by the upregulation of inducible NOS and heme oxygenase-1 
previously proposed (Brown and Bicknell 2001). 
Oxidative stress can occur and their associated consequences have been 
discussed, it is important to examine how oxidative stress can be quantified via 
biomarkers indicative of oxidative stress levels. Biomarkers of oxidative stress have been 
investigated for their association with the development and progression of several cancer 
types, in particular breast cancer. Oxidative stress mechanisms may be involved in 
several known breast cancer risk factors, including obesity and daily alcohol intake, and 
circulating estrogen levels. Breast cancer cells are susceptible to oxidative damage and 
have high levels of oxidative stress, including protein damage, DNA damage, and lipid 
peroxidation. In addition, several breast cancer risk factors may alter levels of 
endogenous oxidative stress (Lee et al. 2017). Biomarkers of oxidative stress have been 
investigated for their association with the development and progression of several cancer 
types, and in particular breast cancer, as oxidative stress mechanisms may be involved in 
several known breast cancer risk factors, including obesity and daily alcohol intake, and 
circulating estrogen levels. Lee et al. 2017). Some studies have reported that higher levels 
of oxidative stress are associated with obesity and adipose tissue. The finding of higher 
levels of oxidative stress and increased risk of postmenopausal breast cancer could reflect 
the known obesity and postmenopausal breast cancer association. Analyses conducted 
and stratified by BMI found a positive association among women with higher BMI, but 
not among women with lower BMI (Lee et al. 2017). In addition to its role in cancer cell 
biology, oxidative stress plays a critical role in cancer treatment, with cytotoxic therapies 
increasing oxidative damage to potentially kill tumor cells. Beyond cancer treatment, 
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oxidative stress from endogenous (e.g., metabolism, immune response) and exogenous 
sources (e.g., ionizing radiation, smoking, chemicals) may result in changes in the 
metabolic pathways in tumor cells, tumor vascular networks, and tumor macrophage 
infiltration. These alterations can impact not only tumor progression but also cancer cell 
adaption to oxidative stress, potentially leading to increased resistance to therapy, 
angiogenesis, and increased risk of metastasis. Due to the critical role of oxidative stress 
mechanisms in both cancer treatment and potentially cancer metastasis, it has been 
suggested that oxidative stress may be particularly important in cancer prognosis (Lee et 
al. 2017). 
A primary biomarker used to quantify oxidative stress is protein carbonylation. 
Protein carbonylation is a form of protein oxidation typically promoted by reactive 
oxygen species. It usually refers to a process that forms reactive ketones or aldehydes that 
can be reacted by 2,4-dinitrophenylhydrazine (DNPH) to form hydrazones. Direct 
oxidation of side chains of lysine, arginine, proline, and threonine residues, among other 
amino acids, in the “primary protein carbonylation” reaction produces DNPH detectable 
protein products (Suzuki et al. 2010). The DNPH derivatizable protein products can also 
be formed in the “secondary protein carbonylation” reaction via the addition of aldehydes 
such as those generated from lipid peroxidation processes. The DNPH protein products 
formed from these secondary reactions are the ones of importance. Oxidative 
decomposition of polyunsaturated fatty acids initiates chain reactions that lead to the 
formation of a variety of carbonyl species (three to nine carbons in length). The most 
reactive and cytotoxic of these species are α,β-unsaturated aldehydes (4-hydroxy-trans-2-
nonenal and acrolein), di-aldehydes (malondialdehyde and glyoxal), and keto-aldehydes 
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(4-oxo-trans-2-nonenal) (Suzuki et al. 2010). Despite the biology of oxidative protein 
modifications being complex and incompletely defined, protein carbonylation and 
chemistry of the reactions that give rise to carbonyl groups have been well characterized.  
In addition to the well-established roles of protein carbonylation in oxidative 
stress, this protein oxidation process may also play roles in cell signal transduction 
(Suzuki et al. 2010). This suggests that cellular regulatory mechanisms of protein 
carbonylation may be complex, which might include the means to promote and eliminate 
protein carbonyls in the body. While enzymatic reversal of the protein–carbonyl 
modifications has not yet been detected, an enzymatic reversal mechanism for protein–
methionine sulfoxide modifications exits and may play a role in the regulation of protein 
carbonylation (Suzuki et al. 2010). As protein carbonylation is irreversible though, the 
modified proteins must be degraded by the cell’s proteasomal system. Cells can degrade 
proteins in two different ways — ATP-ubiquitin dependent by the 26S proteasome and 
ATP-ubiquitin independent by the 20S proteasome (Fedorova et al. 2013). Numerous 
studies have demonstrated that oxidatively damaged proteins are degraded preferentially 
by the 20S proteasome, whereas the activity of the 26S proteasome significantly 
decreased during oxidative stress. Partially unfolded (oxidized or carbonylated) proteins 
present hydrophobic moieties recognized by the 20S proteasome system. In severe 
oxidative conditions, however, extensive protein carbonylation yields protein aggregates, 
which can block the 20S proteasome (Fedorova et al. 2013). In addition to the absence of 
a mechanism to reverse these modifications, cellular enzymes cannot repair carbonylated 
proteins, resulting in an aggregation of carbonylated proteins. Basal levels of cellular 
carbonylation are around two mmol/g protein, whereas severe oxidative conditions can 
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increase this level up to threefold, which corresponds to one carbonylation site per 4,000 
residues (Fedorova et al. 2013). If not eliminated, this aggregation of carbonylated 
proteins will result in cell death. These pathophysiologic roles of protein carbonylation in 
oxidation stress and oxidant signaling suggest that compounds, which regulate carbonyl 
content, may have clinical value. An alternative strategy to the antioxidant intervention 
based on compounds acting as free radical scavengers is to detoxify oxidative-derived 
carbonyl reaction products. Trapping of lipid-derived reactive carbonyl species 
(identified as the chemical intermediates between hyperglycemia, hyperlipidemia, and 
their complications) seems to be very promising, and represents a new therapeutic target 
on which the efforts of the medicinal chemists should focus in the near future (Suzuki et 
al. 2010). 
Many assays are available for the detection of protein carbonyls, but in order to 
keep matters concise, only the method used in the experimental section of this paper will 
be discussed. Highly sensitive assays for the detection of protein carbonyls involve the 
derivatization of the carbonyl group with 2,4-dinitrophenylhydrazine (DNPH), which 
leads to the formation of a stable 2,4-dinitrophenyl hydrazine-substituted product. The 
development of the antibody against DNPH-derivatized proteins was a revolutionary step 
in changing the approach to studying carbonylated proteins by allowing for the use of 
immunological techniques. More recently, these methods contributed to a rapid progress 
in proteomic analyses of carbonylated proteins using two-dimensional gel 
electrophoresis, followed by immunoblotting and mass spectrometry. This redox 
proteomics approach allowed for the identification of carbonylated proteins in various 
diseases in humans, animals models, and cell models, and has provided important 
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information to biologists by describing the effects of modifications by carbonyl species 
on protein function, as well as the consequences of such modifications at the cellular 
level (Suzuki et al. 2010). The measurement of protein carbonyls following their covalent 
reaction with DNPH has become the most widely utilized measure of protein oxidation in 
several human diseases (Dalle-Donne et al. 2003). The stable DNP adduct can be 
detected by various means. The DNP group itself absorbs ultraviolet light so that the total 
carbonyl content of a protein or mixture of proteins can be quantified by a 
spectrophotometric assay, which can be coupled to protein fractionation by high-
performance liquid chromatography (HPLC) to give greater sensitivity and specificity 
than measuring total carbonyls in a protein mixture (Dalle-Donne et al. 2003). However, 
more work has to be done in order to identify the molecular nature of the carbonyls, that 
is, which amino acid residues have been damaged and on what proteins in human tissues 
and body fluids. In the last few years, the identification of carbonylated proteins has been 
facilitated by the availability of commercial specific antibodies to anti-DNP that allow 
their detection by immunoblotting analysis in analogy, for example, with the protocols 
for the study of phosphorylated proteins. Immunoblotting assays based on the use of anti-
DNP antibodies have been developed in an attempt to identify oxidatively damaged 
proteins in human tissues and body fluids. The carbonyl content in individual proteins is 
assessed by one-dimensional (1D) or two-dimensional (2D) sodium dodecyl sulfate 
(SDS) gel electrophoresis followed by Western blot immunoassay (oxyblot) (Dalle-
Donne et al. 2003). These two methods have significantly more sensitivity and specificity 
than all other total carbonyl assays, but they are only semiquantitative. In the method 
previously mentioned, DNPH-derivatized proteins are separated by molecular weight 
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using polyacrylamide gel electrophoresis in the presence of SDS-PAGE, blotted to an 
adsorbent, porous membrane, and visualized by immunostaining with antibodies that 
recognize the DNP portion of the hydrazone (Dalle-Donne et al. 2003). The Western blot 
immunoassay used in this method has the advantage of avoiding complications such as 
incomplete removal of the free DNPH before spectrophotometric measurement, as it 
detects only DNP groups conjugated to proteins. Small amounts of free DNPH, which 
may remain in a sample for electrophoresis, do not react with the anti-DNP antibodies 
even if they bind to transfer membranes. Furthermore, the carbohydrate groups in 
glycoproteins have no apparent effect in the assay (Dalle-Donne et al. 2003). 
The purpose of this experiments conducted in this study were to assess how 
effectively different compounds performed when tested for antioxidant capabilities. The 
compounds used were vitamin E, CoQ10, lovastatin, and hydrogen peroxide. The 
hypothesis being tested is that vitamin E, CoQ10, and lovastatin will all exhibit 
antioxidant effects on the treated cancer cells, while hydrogen peroxide should cause 
there to be a higher level of oxidative stress within the cells due to its oxidative nature.
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Chapter 2: Oxidative Stress-Associated Carbonylation in Breast Cancer Cells 
I.) Introduction 
Reactive oxygen species (ROS) are simply chemically reactive species containing 
oxygen, and in a physiological context, they are natural byproducts of normal cell 
metabolism. However, when reactive oxygen species reach critical levels inside of cells, 
cancerous and non-cancerous cells alike experience oxidative stress, which affects 
numerous biological mechanisms within these cells. Antioxidants, on the other hand, are 
compounds that inhibit oxidation. Antioxidants terminate the oxidative chain reactions 
that produce stress within cells, helping to maintain a homeostatic balance. Additionally, 
oxidative stress levels inside cancer cells can be quantified using biomarkers that are 
associated with this stress, and in this paper, protein carbonylation is the biomarker of 
choice. Specifically, the experiments presented determine the level of proteins 
carbonylated from lipid aldehyde groups produced from “secondary protein 
carbonylation” reaction via the addition of aldehydes such as those generated from lipid 
peroxidation processes. The driving force behind the experiments presented is to assess 
the effectiveness of different compounds as antioxidants in reducing the level of 
oxidative stress within triple-negative breast cancer cells. After cells have been incubated 
in their respective compounds, oxidative stress levels will be quantified via protein 
carbonylation levels observed from performing the oxyblot technique. 
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II.) Materials and Methods 
Cell Culture/Compound Treatment: 
Human breast tumor cell line MDA-MB-231-derived subclone BoM1833 (BoM, 
bone metastatic) was originally developed by the Massagué group at Memorial Sloan 
Kettering Cancer Center, New York City, New York.  The cells were maintained in 
RPMI 1640 media with L-glutamine (2 mM) (Corning), supplemented with fetal bovine 
serum [FBS, 10% (v/v), Hyclone], penicillin (50 units/mL) and streptomycin (50 µg/mL) 
(Lonza) and normacin (2 µg/mL) (Invivogen).  For method development, two previously 
collected BoM cell pellet samples were used (passage #11 and #7, respectively, stored at 
−20°C).  To quantify the effects of compound treatment on protein carbonylation, BoM 
cells were seeded at the density of 0.5 x 106 cells/mL in a volume of 1 mL/well of 12-
well plate.  After overnight incubation in a humidified environment (5% CO2:95% Air) at 
37°C, cells were washed once with RPMI 1640, and then 0.5 mL of RPMI 1640 with 
FCS (10%) and antibiotics were added to each well. Compounds were prepared as stock 
solutions in DMSO (except H2O2) and diluted with the serum- and antibiotic-free RPMI 
1640.  The working solutions containing compounds were added to the wells in a volume 
of 500 µL to achieve the specified final concentrations.  For control wells, 500 µL of 
serum- and antibiotic-free RPMI 1640 were added. Cells were then incubated at 37°C for 
25 hours. The layout for the 12-well plate once the compounds were added to each well is 
shown in Table 1. 
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Table 1: 12-well plate layout for cell cultures treated with compounds 
 1 2 3 4 
A Vitamin E  
10 µM 
Vitamin E 
100 µM 
Lovastatin  
1 µM 
Lovastatin  
10 µM 
B CoQ10 
 1µM 
CoQ10  
10 µM 
H2O2  
10 µM 
H2O2  
30 µM 
C Media 
Control 
Media 
Control 
Media 
Control 
H2O2  
100 µM 
 
Protein Extraction with MPER Protocol: 
Mammalian protein extraction reagent (ThermoFisher), or MPER, is a cell lysis 
reagent that dissolves cell membranes to extract and solubilize total protein from most 
cell compartments. It is a reagent that works quickly and provides minimal interference 
with biological applications. For the lysis of previously frozen cell pellet, a change was 
made to the traditional MPER protocol. For the BOM passage #7 (P7) cell pellet sample 
and half of the BOM passage #11 (P11) pellet sample, β-mercaptoethanol (1% v/v) was 
added to the MPER solution. For those with β-mercaptoethanol added, a (+) designation 
was added and a (–) designation to those without in order to differentiate between 
samples. A master mix was created for (+) cells that consisted of 940 µL of MPER, 50 µL 
of 20x protease inhibitor (Sigma), and 10 µL of β-mercaptoethanol. For (–) cells, or those 
without β-mercaptoethanol, the same mixture was used but 10 µL of ddH2O was added in 
place of β-mercaptoethanol. The cell pellet was washed once with serum-free RPMI1640 
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media and cells pelleted by centrifugation at 2,500 x g for 10 minutes, and after, the 
supernatant was discarded. P7 cells were split into two different tubes with about 90 µL 
in each tubes. The appropriate master mixes were added to their respective tubes, and the 
final volume of the three tubes was approximately 375 µL for each of the three tubes. As 
the mixture was added, it was pipetted up and down in order to resuspend the pellet. The 
three tubes were then shaken gently for 10 minutes and cell debris was removed by 
centrifugation at ~14,000 x g for 15 minutes at room temperature. After centrifugation, 
the supernatant of each tube was transferred to a new tube for analysis via BCA protein 
assay (ThermoFisher). For the acquisition of cell lysates from cells in 12-well plate, 10x 
PBS (Fisher Scientific) was diluted to 1x with ddH2O and kept on ice, and 1900 µL of 
MPER was combined with 100 µL of protease inhibitor (PI). Once the two solutions were 
prepared, cells in the 12-well plate previously mentioned were removed from incubation 
and observed underneath the microscope, making sure to note the conditions of each 
well. The condition media was then removed from each well. The cells were washed with 
2 mL of ice cold 1x PBS/ well and then transferred back out, making sure to remove as 
much liquid as possible. A mixture of 150 µL of MPER + PI solution was added to each 
well, and the plate was kept on ice for ~10 minutes with gentle rocking. The cell lysates 
were then scraped from each well, transferred to individual, cooled tubes, and centrifuged 
at 10,000 xg for 5 minutes. The supernatant from each tube was then transferred to a new, 
cooled tube. The protein concentration in each sample is determined by the BCA protein 
assay. 
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Protein Concentration and Quantification 
Once the proteins had been extracted using the MPER protocol, the samples were 
analyzed using a micro BCA protein assay kit. The standards were prepared from a 2 
mg/mL BSA stock solution, and a working reagent was made from the three solutions 
provided: 1400 µL of MA, 1344 µL of MB, and 56 µL of MC solutions, which is at a 
25:24:1 ratio. The three solutions were combined to make a total volume of 2800 µL.  
Each well contained 100 µL of sample or standard and 100 µL of working reagent for 
200 µL total in each well. Additionally, the method in which the dilutions of the 
standards were achieved can be observed in Table 2, and the dilutions for the samples 
were achieved in a similar method. The plate layout of the 96-well plate can be seen in 
Table 3. After the dilutions were completed, the samples added, and the working reagent 
was added, the plate was incubated at 37 °C for 2 hours. After it was allowed to cool to 
room temperature, the plate was read at 562 nm. The concentration readings observed 
after normalization for background interference (620 nm) can be observed in the results 
section in Table 5. Using the OD 562 values obtained from analysis of the protein 
standards, a graph was created from plotting protein standard concentrations vs. OD 562 
using a linear regression trendline in order to determine the concentration of the protein 
in each sample. The graph and associated trendline can also be viewed in the results 
section in Figure 1.  
Table 2: Dilutions of BCA Standards 
Tube BSA Standard 
Concentration 
(µg/mL) 
Volume of Standard 
(µL) 
Volume of ddH2O 
(µL) 
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A 40 10 (Stock) 490 
B 30 7.5 (Stock) 492.5 
C 20 250 (Tube A) 250 
D 15 250 (Tube B) 250 
E 10 250 (Tube C) 250 
F 7.5 250 (Tube D) 250 
G 5 250 (Tube E) 250 
H 0 0 250 
 
 
Table 3: Layout of 96-well plate for first BCA protein assay experiment 
 1 (BSA) 2  3 4 5 
A 0 P7 (+) 1:10 P11 (-) 1:10 P7 (+) 1:100 “Solvent” 
1:100 
B 5 P7 (+) 1:20 P11 (-) 1:20 P7 (+) 1:200 “Solvent” 
1:200 
C 7.5 P7 (+) 1:40 P11 (-) 1:40 P7 (+) 1:300 “Solvent” 
1:300 
D 10 P7 (+) 1:100 P11 (-) 
1:100 
P7 (+) 1:400 “Solvent” 
1:400 
E 15 P11 (+) 1:10 MPER + PI P11 (+)  
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1:10 1:100 
F 20 P11 (+) 1:20 MPER + PI 
1:20 
P11 (+) 
1:200 
 
G 30 P11 (+) 1:40 MPER + PI 
1:40 
P11 (+) 
1:300 
 
H 40 P11 (+) 
1:100 
MPER + PI 
1:100 
P11 (+) 
1:400 
 
 
For the second BCA protein assay experiment, the BCA standards and their dilutions 
were performed in the same method as shown in Table 2, and the working solution for 
this round was again made using the three master solutions provided. 1500 µL of MA, 
1440 µL of MB, and 60 µL of MC were combined to make a final volume of 3000 µL. 
The plate layout for the standards and samples of this experiment are shown in Table 4. 
As with the previous round, 100 µL of sample/standard and 100 µL of working solution 
were added to each well. The 96-well plate was incubated at 37 °C for 1 hour and 47 
minutes. The plate was then read at 562 nm. As before, the concentration readings 
observed after normalization for background interference can be observed in the results 
section in Table 6. Using the OD 562 values obtained from analysis of the protein 
standards, another graph was created from plotting concentration vs. OD 562 using a 
linear regression trendline in order to determine the concentration of the protein in each 
sample. The graph and associated trendline can also be viewed in the results section in 
Figure 2. 
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Table 4: Layout of 96-well plate for second BCA protein assay experiment 
 7 (1:50) 8 (1:50) 9 (BCA) 10 (1:100) 11 (1:200) 12 
A Vitamin E 
10 µM 
H2O2 10 
µM 
0 Vitamin E 
10 µM 
Vitamin E 
10 µM 
H2O2 10 µM 
(1:100) 
B Vitamin E 
100 µM 
H2O2 10 
µM 
5 Vitamin E 
100 µM 
Vitamin E 
100 µM 
H2O2 10µM 
(1:200) 
C Lovastatin 
1 µM 
MPER 
+PI 
7.5 Lovastatin 
1 µM 
Lovastatin 
1 µM 
MPER + PI 
(1:100) 
D Lovastatin 
10 µM 
MPER + 
PI 
10 Lovastatin 
10 µM 
Lovastatin 
10 µM 
MPER +PI 
(1:200). 
E CoQ10 
1µM 
 15 CoQ10 
1µM 
CoQ10 
1µM 
 
F CoQ10  
10 µM 
 20 CoQ10   
10 µM 
CoQ10   
10 µM 
 
G MC 1  30 MC 1 MC 1  
H MC 2  40 MC 2 MC 2  
 
Table 5: Protein concentration readings (µg/mL) at 562 nm from first BCA protein assay 
(correlating to Table 3). 
 1 2 3 4 5 
A 0 3.875 1.912 2.632 3.875 
B 0.074 3.875 1.27 1.499 3.852 
C 0.104 3.875 0.797 0.903 3.055 
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D 0.170 2.347 0.392 0.700 2.438 
E 0.229 3.875 0.052 1.876 - 
F 0.339 3.875 0.034 0.982 - 
G 0.418 3.875 3.875 0.672 - 
H 0.685 2.394 3.875 0.488 - 
 
In Table 5, the results obtained from the first BCA protein assay are shown. The 
readings observed in the table are the concentration (µg/mL) of the protein samples, and 
the purpose of obtaining these concentrations was so the amount of protein in each 
sample could be normalized for the oxyblot experiment. However, only the bolded values 
in Table 5 could be used because the rest of the protein concentrations were outside of the 
range of the protein standards given in column 1. 
 
 
 
 
 
 
 
Figure 1: Protein standard concentration vs. OD 562 in first BCA protein assay 
 Using the concentration of the viable protein standards from Table 5, a graph 
plotting the protein concentration against OD 562 was created, and a line of best-fit using 
linear regression was used to give us the formula observed in Figure 1. From this 
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-0.100	0.000	
0.100	0.200	
0.300	0.400	
0.500	
0	 5	 7.5	 10	 15	 20	 30	
O
D
	5
62
	
Protein	Concentration	(μg/mL)		
Protein	Concentration	Standard	
	45	
formula, the amount of actual protein in each sample was calculated, and this was a 
crucial step for the oxyblot experiments performed because the same amount of protein 
was required in each sample for the results to be accurate.  
 
Table 6: Protein concentration (µg/mL) readings at 562 nm from second BCA protein 
assay (correlating to Table 4). 
 7 8 9 10 11 12 
A 0.217 5 x 10-3 0 0.124 0.063 2 x 10-3 
B 0.205 - 0.075 0.074 0.030 - 
C 0.208 - 0.085 0.111 0.054 5 x 10-3 
D 0.189 - 0.11 0.108 0.072 - 
E 0.229 - 0.181 0.144 0.064 - 
F 0.235 - 0.240 0.114 0.058 - 
G 0.190 - 0.123 0.123 0.064 - 
H 0.197 - 0.120 0.120 0.061 - 
 
 The results from the second BCA protein assay experiment are shown in Table 6. 
Again, the purpose of obtaining these values was so that normalization of the amount of 
protein present in each sample during the subsequent oxyblot could be performed. Unlike 
the first protein assay, the majority of the sample concentrations fell within the range of 
the standards, and they can be seen in bold in Table 6. Because the number of lanes in the 
SDS-PAGE gel limited us to twelve, the highest concentration of each sample that fell 
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within the standard range was used. In using the highest available concentration of each 
sample, the effects of the compounds could be better observed in the oxyblot experiment. 
 
 
 
 
 
 
Figure 2: Protein concentration vs. OD 562 graph in second BCA protein assay 
Using the viable concentrations gathered from Table 8, the graph in Figure 3 was 
created by plotting the protein standard concentrations against OD 562, and after this had 
been completed, a line of best fit using the linear regression method was added in order to 
obtain the formula observed in Figure 3. Again, this formula is crucial for ensuring an 
equal amount of protein is present in each sample during the oxyblot technique. 
Oxyblot 
The oxyblot technique consists of a multistep protocol that involves a 
derivatization reaction, separation of proteins by SDS-PAGE, transfer onto a membrane, 
incubation with necessary antibodies, and exposure to film. A commercial kit (Millipore) 
was used to detect protein carbonylation. Two rounds of oxyblot were performed, and the 
first step in the process is the derivatization reaction. For the derivatization reaction, two 
tubes of each sample are used. The purpose of this is to provide a negative control and a 
non-control sample. Using the data collected from the BCA protein assay, the amount of 
protein in each sample was calculated, and this was done to standardize the amount of 
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protein that would be used for the reaction. For the first round of oxyblot, 7.0 µL of 
protein was used for the lowest protein concentration sample, which was P11 (-). 1.2 µL 
was used for P7 (+), and 1.5 µL was used for P11 (+), and the final amount of protein in 
all samples was approximately 5 µg in a total volume of 7 µL. For the two higher 
concentration samples, MPER made up the rest of the missing volume. For all samples, 3 
µL of 20% SDS were also used. For negative control samples, 10 µL of derivatization 
control were added, and for non-control, 10 µL of DNPH were added. After all samples 
incubated at room temperature for 15 minutes, 7.5 µL of neutralizing solution was added 
to each.  
Preparation for gel loading was the next step in the protocol. A gel loading buffer 
was created in preparation for gel loading. The gel-loading buffer consisted of 190 µL of 
Laemmli 2x sample buffer (Bio-Rad) and 10 µL of β-mercaptoethanol. For the molecular 
weight standards, 10 µL of 2x loading buffer and 10 µL of pre-stained molecular weight 
standards was used. For the oxyblot standard, 2.5 µL of standard, 7.5 µL of ddH2O, and 
10 µL of 2x loading buffer were added. For the samples, 15 µL of sample and 15 µL of 
2x loading buffer were added to each well. Once all the samples and standards were 
prepped, they were ready to load in the gel. The gel was then loaded and run at 70 volts 
for 20 mins, 57 volts for 1 hour, and 22 volts for 40 minutes in a Tris-Hepes-SDS running 
buffer. The layout of the gel lanes can be viewed in Table 7. The proteins were then 
electroblotted to a nitrocellulose membrane. An electroblot transfer buffer was prepared 
using 100 mL of 10x TG buffer, 100 mL of methanol, and 800 mL of ddH2O. The 
transfer ran at ~140 milliamps for 40 minutes, 150 for 20 minutes, and 50 for 15 minutes. 
Once the transfer had been completed, the nitrocellulose membrane was blocked 
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overnight at 4°C in a 1% BSA/PBS-T buffer. The PBS-T was prepared by combining 50 
mL of 10x PBS, 0.25 mL of Tween-20, and 449.75 mL of ddH2O. This was then used to 
make the blocking buffer by combining 0.902 g of BSA with 90 mL of PBS-T. The 
blocking buffer was then poured off, and 1:150 solution consisting of 60 µL of primary 
antibody (Millipore) and 9 mL of blocking buffer. The membrane was incubated in the 
solution for approximately one hour at room temperature with gentle shaking. It was then 
rinsed twice with 1x PBS-T, washed with 1x PBS-T once for 15 minutes, and then twice 
for five minutes each. A 1:300 solution consisting of 30 µL of secondary antibody 
(Millipore) and nine mL of blocking buffer were added to the membrane, and the 
membrane was incubated for another hour at room temperature, with gentle shaking. It 
was then washed as previously explained and placed protein side up and covered to 
prevent light from hitting it. SuperSignal West Femto Maximum Sensitivity Substrate 
was used as the chemiluminescent reagent. The membrane was incubated in this reagent 
for 1 minute, and then, the excess reagent was drained off. The membrane was then 
placed protein side up in the film cassette and exposed for approximately thirty seconds 
to develop. 
For the second round of oxyblot, the protocol was performed in the same manner 
as previously described, but different chemicals were used. For the derivatization 
reaction, H2O2 had the lowest protein concentration, so 7.0 µL were used. For the other 
samples, media control used 2.8 µL, 100 µM Vitamin E used 3.8 µL, 10 µM CoQ10 used 
3.0 µL, and 10 µM lovastatin used 3.0 µL. As before, the missing volume needed to make 
7 µL was filled in by MPER. The gel was then loaded and run at 70 volts for one hour 
and 20 minutes and 100 volts for 20 minutes. The layout for the second SDS-PAGE gel 
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can be seen in Table 8. The proteins were then transferred at 150 milliamps for one hour. 
The membrane was then transferred into the blocking solution for one hour at room 
temperature, and the primary and secondary antibodies were added in the same method as 
before and all other steps were the same as previously described. 
 
Table 7: Lane layout for first SDS-PAGE gel 
Lane 1 Lane 2 Lane 3 Lane 4 Lane 5 Lane 6 Lane 7 Lane 8 
Molecular 
Weight 
Marker 
Oxyblot 
Standard 
P11 (+) 
Control 
P11 (+) P11 (-) 
Control 
P11 (-) P7 (+) 
Control 
P7 (+) 
 
Table 8: Lane layout for second SDS-PAGE gel.  
1 2 3 4 5 6 7 8 9 10 11 12 
Molecular 
Weight 
Marker 
Oxyblot 
Standard 
Media 
Control 
Media H2O2 
Control 
H2O2 VE 
Control 
VE CoQ10 
Control 
CoQ10 Lov 
Control 
Lov 
 
III.) Results 
The following is the results gathered from each individual experiment. The results 
consist of Figure 3 and Figure 4, which show the gels obtained from the oxyblot 
experiments performed. 
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Figure 3: Effects of extraction conditions on breast cancer cell carbonylation 
 Figure 3 shows the results from the first oxyblot experiment. The primary purpose 
of this experiment was to perfect the oxyblot protocol in addition to observing the effects 
of adding β-mercaptoethanol to the samples. It was observed that samples containing β-
mercaptoethanol exhibited no results for protein carbonylation, but the opposite was 
observed for the sample without β-mercaptoethanol, with it blurring into the surrounding 
lanes 
 
 
 
Figure 4: Impact of antioxidants and oxidants on carbonylation in breast cancer cells 
 
Oxyblot CoQ10 
(-)     (+) 
  Media 
(-)      (+)  
Vitamin E 
(-)       (+) 
Lovastatin 
(-)       (+) 	
21 kDa è  
29 kDa è  
43 kDa è  
68 kDa è  
97.4 kDa è  
  H2O2 
(-)      (+) 
29 kDa è  
43 kDa è  
Oxyblot    P7 (+) 
(-)        (+) 
  P11 (+) 
(-)       (+) 
  P11 (-) 
(-)      (+) 
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 Figure 4 shows the results from the second oxyblot experiment. The lanes labeled 
(-) were the negative control samples, and the (+) labeled lanes are the samples that 
should exhibit protein carbonylation. Observation of Figure 4 shows low levels of protein 
carbonylation at proteins with a molecular weight of 29 kDa and 63 kDa in the media, 
CoQ10, and lovastatin samples but nothing particularly significant. Although hydrogen 
peroxide is known to induce an increase in oxidative stress levels, no protein 
carbonylation was present in the oxyblot. This is most likely due to the cells being 
severely degraded by the compound treatment, which resulted in the death of most of 
them. However, the vitamin E sample in Figure 4 shows high levels of protein 
carbonylation at these proteins, which is indicative of increased oxidative stress within 
the cells.  
IV.) Discussion 
The protein carbonylation levels in the media control sample were expected and 
were used as a baseline of normal cancer cell levels of oxidative stress within cancer 
cells. From the level of protein carbonylation exhibited by the media sample, the relative 
increase or decrease in protein carbonylation can inferred. For hydrogen peroxide, there 
should have been severe levels of protein carbonylation, as it is known to induce high 
levels of oxidative stress, but because the cells were mostly dead upon retrieval from 
plate, the sample did not work well for this experiment. For CoQ10 and lovastatin, the 
samples did not experience a significant increase or decrease in the level of protein 
carbonylation relative to the media control. But, CoQ10 is considered to exhibit 
antioxidant capabilities according to Portakal et al. (2000). Furthermore lovastatin is 
thought to have some degree of antioxidant capacity as well according to data from 
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Kumar et al. (2011). The most intriguing finding from the experiments presented is the 
level of protein carbonylation induced by vitamin E in breast cancer cells. Vitamin E has 
been used for as an antioxidant for several experiments, and as a result, there is literature 
assessing its effectiveness as an antioxidant. In some cases, vitamin E is shown to reduce 
the oxidative stress within cells, thereby decreasing the level of protein carbonylation. 
When vitamin E is present with lipids in the cell membrane, it works to inhibit cancer 
formation through the neutralization of ROS. A direct relationship was also established 
between vitamin E deficiencies and lipid peroxide production (Nathan et al. 2011). In 
addition, vitamin E and epicatechin treatment appeared to ameliorate the effects of toxic 
oxidative stress induced by nicotine by scavenging free radicals and enhancing the effects 
of antioxidant enzymes (Al-Malki and Moselhy 2013). Data collected by Garibaldi et al. 
1994 also suggests the involvement of tocopherols, such as vitamin E, in the prevention 
of oxidative damage by of circulating proteins. Considering the literature in favor of 
vitamin E’s effectiveness as an antioxidant, it was interesting that the cells treated with 
vitamin E expressed higher levels of protein carbonylation than was present in the media 
control. Although there is no definitive answer for this, one possible reason is vitamin E, 
in high doses, may exhibit prooxidative qualities (Kodentsova et al. 2013). Therefore, the 
prooxidative qualities induced by vitamin E could result in the increase of oxidative 
species within the cell, which would result in the enhanced level of protein carbonylation 
observed in Figure 4. 
V.) Conclusion 
In conclusion, several different compounds were assessed for their effects as 
antioxidants during the experiments presented. Although the majority of compounds did 
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not produce significant results, vitamin E surprisingly exhibited an oxidant, not 
antioxidant, capacity. This result is interesting because vitamin E is a compound 
traditionally considered to have antioxidant qualities, but the findings presented in this 
study present a different picture. Although the results from these experiments are not 
definitive, they do provide a different perspective on the compounds used and their 
ability to reduced oxidative stress and lower protein carbonylation levels. In order to help 
these results become more definitive, the experiments should be repeated with another 
two gels, and in addition to running two more gels, imageJ software could be used to 
quantify the concentration in each band. 
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